Page last updated: 2024-09-03

5-fluorodopamine and Neuroendocrine Tumors

5-fluorodopamine has been researched along with Neuroendocrine Tumors in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Karges, W; Mottaghy, FM; Van Binnebeek, S1
Gesuwan, K; Herscovitch, P; Hughes, MS; Kebebew, E; Kitano, M; Libutti, SK; Linehan, WM; Millo, C; Nilubol, N; Phan, GQ; Rahbari, R; Venkatesan, AM; Webb, RC1
Arola, J; Asa, SL; Sane, T; Schalin-Jäntti, C1

Trials

1 trial(s) available for 5-fluorodopamine and Neuroendocrine Tumors

ArticleYear
Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease.
    Surgery, 2011, Volume: 150, Issue:6

    Topics: Adolescent; Adult; Aged; Dopamine; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed; von Hippel-Lindau Disease; Young Adult

2011

Other Studies

2 other study(ies) available for 5-fluorodopamine and Neuroendocrine Tumors

ArticleYear
Functional imaging of neuroendocrine tumors.
    Methods in molecular biology (Clifton, N.J.), 2011, Volume: 727

    Topics: 5-Hydroxytryptophan; Animals; Contrast Media; Dihydroxyphenylalanine; Dopamine; Ephedrine; Etomidate; Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Peptides; Positron-Emission Tomography; Radioactive Tracers; Radiopharmaceuticals; Somatostatin

2011
Recurrent acute-onset Cushing's syndrome 6 years after removal of a thymic neuroendocrine carcinoma: from ectopic ACTH to CRH.
    Endocrine pathology, 2013, Volume: 24, Issue:1

    Topics: ACTH Syndrome, Ectopic; Adrenocorticotropic Hormone; Adult; Corticotropin-Releasing Hormone; Cushing Syndrome; Disease Progression; Dopamine; Humans; Hydrocortisone; Ki-67 Antigen; Male; Neuroendocrine Tumors; Radiopharmaceuticals; Thymus Neoplasms

2013